Revisiting the effects of menopause on the skin: Functional changes, clinical studies, in vitro models and therapeutic alternatives.

Menopause is a stage in a woman's life characterized by twelve months of amenorrhoea. This transition happens due to changes in ovarian follicular activity, leading to endocrine, biological and clinical modifications. The main hormones related to these changes and symptoms are oestradiol, LH, FSH, AMH, Inhibin B and GnRH. It is important to point out that the skin is very affected by all these hormone changes, leading to a decrease in collagen content, water content, elasticity, thickness and impacting on all skin layers quality. Aiming to help women go through this period of their lifetimes with a better quality of life, cosmetic and pharmaceutical industries have studied formulations to improve skin quality. In order to study the safety and efficacy of these products, in vitro methods have been developed in order to mimic menopause and aged skin. In addition to that, many clinical methodologies for skin features assessment have also been improved and applied to evaluate the efficacy of treatments or compounds for menopause. Studying and improving skin models and skin evaluation methodologies may help in the identification of therapeutic targets, treatments, drugs and cosmetics along with new insights for future research in the dermatology field.

Dose-dependent cell necrosis induced by silica nanoparticles.

In recent years, much attention has been given to nanoparticles (NPs) due to their many possible applications, and as research has progressed, these NPs have become valuable tools for medical purposes. Among many different types of NPs, silica nanoparticles (SiO2NPs) have been specifically evaluated for medical purposes and have also been used in many different types of products. Although SiO2NPs have already been applied and are believed to be nontoxic, there is still a concern regarding possible adverse effects that may be triggered after SiO2NP exposure. Therefore, in the present study, we employed a recommended cell line (BALB/c 3T3) for the toxicity evaluation to investigate the cytotoxic effects of SiO2NPs produced by chemical synthesis at a laboratory scale. First, we employed OECD guideline 129 in order to evaluate cytotoxicity effects and also estimate the starting doses for acute oral systemic toxicity tests. We evaluated the cytotoxic effects of two types of SiO2NPs (nonfluorescent and fluorescent) and found that they were not significantly different (IC50 = 1986.39 ± 237 µg/mL and IC50 = 1861.13 ± 186.72 µg/mL, respectively). Then, we used the predicted LD50 of both types of SiO2NPs to suggest that they could be categorized as GHS category 4 substances. By ultrastructural evaluation, we found that SiO2NPs are internalized by 3 T3 cells and are located in vacuole-like structures with no other significant changes in cell structure. We also found that SiO2NPs lead to cell necrosis in a dose-dependent manner.

Dose-dependent cytotoxicity of bismuth nanoparticles produced by LASiS in a reference mammalian cell line BALB/c 3T3.

Nanoparticles (NPs) have emerged as new potential tools for many applications in previous years. Among all types of NPs, bismuth NPs (BiNPs) have a very low cost and potential for many applications, ranging from medicine to industry. Although the toxic effects of bismuth have been studied, little is known about its toxicity at the nanoscale level. Therefore, in this study, we aimed to investigate the cytotoxic effects of BiNPs produced by laser ablation synthesis in solution (LASiS) in a reference mammalian cell line to evaluate their cytotoxicity (BALB/c 3 T3 cells). We also stabilized BiNPs in two different solutions: culture medium supplemented with fetal bovine serum (FBS) and bovine serum albumin (BSA). The cytotoxicity of BiNPs in culture medium (IC50:28.51 ±â€¯9.96 µg/ml) and in BSA (IC50:25.54 ±â€¯8.37 µg/ml) was assessed, and they were not significantly different. Second, the LD50 was predicted, and BiNPs were estimated as GHS class 4. We also found that cell death occurs due to apoptosis. By evaluating the interaction between BiNPs and cells at ultrastructural level, we suggest that cell death occurs once BiNPs are internalized. Additionally, we suggest that BiNPs cause cell damage because myelin figures were found inside cells that had internalized BiNPs. To date, this is the first study to assess the cytotoxicity of BiNPs produced by LASiS and to predict the possible LD50 and GHS class of BiNPs.

Procaspase-activating compound-1 induces apoptosis in Trypanosoma cruzi.

Some therapeutics for parasitic, cardiac and neurological diseases activate apoptosis. Therefore, the study of apoptotic proteins in pathogenic organisms is relevant. However, the molecular mechanism of apoptosis in unicellular organisms remain elusive, despite morphological evidence of its occurrence. In Trypanosoma cruzi, the causative agent of Chagas disease, metacaspase 3 (TcMCA3), seems to have a key role in parasite apoptosis. Accordingly, this work provides data concerning TcMCA3 regulation through its interaction with procaspase-activating compound 1 (PAC-1), a procaspase 3 activator. Indeed, PAC-1 reduced T. cruzi epimastigote viability with an IC50 of 14.12 µM and induced loss of mitochondrial potential and exposure of phosphatidylserine, features of the apoptotic process. Notwithstanding, those PAC-1-inducible effects were not conserved in metacyclic trypomastigotes. Moreover, PAC-1 reduced the viability of mammalian cells with a greater IC50 (25.70 µM) compared to T. cruzi epimastigotes, indicating distinct modes of binding between caspases and metacaspases. To shed light on the selectivity of metacaspases and caspases, we determined the structural features related to the PAC-1 binding sites in both types of proteins. These data are important for improving the understanding of the apoptosis pathway in T. cruzi so that TcMCA3 could be better targeted with future pharmaceuticals.

Secretome from resident cardiac stromal cells stimulates proliferation, cardiomyogenesis and angiogenesis of progenitor cells.

In the heart, tissue-derived signals play a central role on recruiting/activating stem cell sources to induce cardiac lineage specification for maintenance of tissue homeostasis and repair. Cardiac resident stromal cells (CRSCs) may play a pivotal role in cardiac repair throughout their secretome. Here, we performed the characterization of CRSCs and their secretome by analyzing the composition of their culture-derived extracellular matrix (ECM) and conditioned medium (CM) and by investigating their potential effect on adipose-derived stem cell (ADSC) and progenitor cell behavior. We confirmed that CRSCs are a heterogeneous cell population whose secretome is composed by proteins related to cellular growth, immune response and cardiovascular development and function. We also observed that CRSC secretome was unable to change the behavior of ADSCs, except for proliferation. Additionally, CM from CRSCs demonstrated the potential to drive proliferation and cardiac differentiation of H9c2 cells and also the ability to induce angiogenesis in vitro. Our data suggest that the CRSCs can be a source of important modulating signals for cardiac progenitor cell recruitment/activation.

The use of human adipose-derived stem cells based cytotoxicity assay for acute toxicity test.

Human adipose-derived stem cells (ADSC) were evaluated as cell culture model for cytotoxicity assay and toxicity prediction by using the neutral red uptake assay (NRU). In this study, we compared ADSC and the murine cell line BALB/c 3T3 clone A31 to predict the toxicity of 12 reference substances as recommended by the Interagency Coordinating Committee on the Validation of Alternative Methods. We predicted the LD50 for RC-rat-only weight and RC-rat-only millimole regressions for both cell culture models. For RC rat-only weight regression, both cells had the same accordance (50%), while for RC rat-only millimole regression, the accordance was 50% for ADSC and 42% for 3T3s. Thus, ADSC have similar capability for GHS class prediction as the 3T3 cell line for the evaluated reference substances. Therefore, ADSCs showed the potential to be considered a novel model for use in evaluating cytotoxicity in drug development and industry as well as for regulatory purposes to reduce or replace the use of laboratory animals with acceptable sensitivity for toxicity prediction in humans. These cells can be used to complete the results from other models, mainly because of its human origin. Moreover, it is less expensive in comparison with other existing models.

Aspectos imunológicos da infecção pelo vírus do papiloma humano (HPV) / Immunological aspects of human papiloma virus (HPV) infection

O vírus do papiloma humano (HPV-human papiloma virus) pode infectar até 80% das pessoas, principalmente as sexualmente ativas. O risco e a sintomatologia da infecção são distintos entre os gêneros. Sabe-se que existem mais de 150 sorotipos e estes são agrupados por seu tropismo. Embora a maioria das infecções siga um curso benigno, a infecção persistente por certos sorotipos pode levar ao desenvolvimento de câncer. Os sorotipos 16 e 18 estão envolvidos com uma forma grave de lesão, acarretando câncer, principalmente do colo do útero. Os sorotipos 6 e 11 são descritos como causadores de verrugas anogenitais. O vírus, de aproximadamente 8.000 pb, se instala na célula e por meio da expressão das oncoproteínas E6 e E7, levando à inibição de proteínas como a p53 e a pRB, importantes na apoptose e na parada do ciclo celular. As vacinas atuais geram imunidade contra os sorotipos 6, 11, 16 e 18. A vacina pode ser tetravalente (quatro sorotipos: 6, 11, 16 e 18) ou bivalente (16 e 18). Ambas apresentam proteção cruzada contra a infecção por sorotipos não inclusos nas vacinas, porém não possuem caráter terapêutico. O presente trabalho teve como proposta revisar os avanços sobre a infecção pelo HPV, os aspectos imunológicos e as vacinas profiláticas disponíveis.

The human papilloma virus (HPV-human papilloma virus) can infect up to 80% of people, especially sexually active. The risk of infection and symptoms are different between the sexes. It is known that there are over 150 serotypes and these are grouped by their tropism. Although most infections follow a benign course, the persistent infection with certain serotypes may lead to the development of cancer. The serotypes 16 and 18 are involved in a severe form of injury, resulting in cancer, particularly cervical cancer. Serotypes 6 and 11 are described as causes of anogenital warts. The virus, approximately 8.000 bp, it installs itself in the cell and through the expression of oncoproteins E6 and E7 leading to inhibition of proteins such as p53 and pRB, important in apoptosis and cell cycle arrest. Current vaccines generate immunity against serotypes 6, 11, 16 and 18. The vaccine can be tetravalent (four serotypes 6, 11, 16 and 18) or bivalent (16, 18). Both have cross-protection against infection by serotypes not included in the vaccines, but have no therapeutic character. This study was proposed to review progress on the HPV infection, the immunological aspects and prophylactic vaccines available.